Last reviewed · How we verify
Alomnertinib Mesilate
Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations.
Alomnertinib mesilate is a third-generation EGFR tyrosine kinase inhibitor that irreversibly binds to and inhibits mutant EGFR, including T790M resistance mutations. Used for Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations.
At a glance
| Generic name | Alomnertinib Mesilate |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Drug class | Third-generation EGFR tyrosine kinase inhibitor |
| Target | EGFR (Epidermal Growth Factor Receptor), particularly mutant forms including T790M |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Alomnertinib is designed to selectively target EGFR mutations commonly found in non-small cell lung cancer, particularly the T790M mutation that confers resistance to first and second-generation EGFR inhibitors. By irreversibly binding to the ATP-binding pocket of mutant EGFR, it blocks downstream signaling pathways that drive cancer cell proliferation and survival. This mechanism allows it to overcome resistance mechanisms that develop during treatment with earlier-generation EGFR inhibitors.
Approved indications
- Non-small cell lung cancer with EGFR mutations, including T790M resistance mutations
Common side effects
- Diarrhea
- Rash
- Nausea
- Fatigue
- Decreased appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alomnertinib Mesilate CI brief — competitive landscape report
- Alomnertinib Mesilate updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI